Redeye provides a preview ahead of Thunderful Groups Q3 2023 report, due on the 15th of November, ex...
SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22...
Obducat publicerade den 3 november 2023 bolagets delårsrapport för det tredje kvartalet 2023, vilken...
Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer.
Redeye continues to see good cost control and highlights that the low y/y sales growth can be partly...
Redeye comments on Flexion Mobile’s preliminary figures for Q3-Q4 and its revised full year guidance...
Cuts 2023 growth guidance to 0-10% (20-40%) Q3 sales below expectaions while Q4 more in-line We expe...
Redeye comments on BioInvent’s TNFR2 project BI-1808 after strong phase I results presented at SITC ...
Redeye updates its estimates following Pagero’s Q3 2023 report, which was more or less in line on th...
3.5pp q-o-q margin expansion a strong statement Adj.
Redeye updates its estimates and valuation after reviewing Tessin's Q3 report, which showed somewhat...
Redeye is encouraged to see the progress made by Scandinavian ChemoTech in the Q3 2023 report, which...
Seasonal slowdown: Q3e sales SEK 30m, EBIT SEK -4m We expect profitability in '25e: sales SEK 157m, ...
Redeye comments on Alelion’s decision to file for bankruptcy.
Redeye provides an update in relation to Optomed’s Q3 2023 report.
Movinn published on November 3rd the company’s Q3-report for 2023.
Tvåsiffrig negativ organisk tillväxt i kvartalet… Med en acceleration av nedstängningen av kopparnät...
ChargePanel AB (publ) meddelade den 2 november att bolaget har ingått ett samarbete med Charge4Go AB...
Divests the smallest group company Hedén Minor effect on estimates, outlook unaffected Trading at 16...
Minor estimate changes Gross margin improvements still on the horizon '24e lease adj.
